Secondary outcomes included leukemia-free survival (LFS), relapse rate, and treatment-related mortality (TRM). In a multivariate analysis, the presence of EMD did not affect either OS (HR 1.00, 95% CI 0.91–1.09), LFS (0.98, 0.89–1.09), TRM (RR 0.92, 95% CI 0.80–1.16, p=0.23) ...
AML中国诊疗指南AML部分.ppt,非移植患者10年生存率达37% N=202 43% 37% 总生存概率 1.0 0.8 0.6 0.4 0.2 0.0 时间 (年) 0 2 4 6 8 10 12 14 Eur J Haematol 2007; 78(6):477-486. 目前三十一页\总数五十五页\编于十点 非移植患者10年无复发生存率达32% N=195 40% 32% 无复发
Acute myeloid leukemia (AML) is a cancer of the bone marrow and the blood that progresses rapidly without treatment. It is a heterogeneous disease with variable prognosis for different patient subpopulations. Despite the advancements in medical research, there is still a significant need for new eff...
the complex pathophysiology of AML, high recurrence rates, patient age-dependent overall survival (OS) at time of diagnosis, and the variable genetic characteristics of blast cells limit the efficacy of treatment and the chance of survival (Bhansali et al.2023; Dohner et al.2022; Sasaki...
Overall survival in t-AML subgroups: treatment modality and age Median OS was 24 months in the entire cohort (95% CI 19.5–28.5) and 5-year OS was 36.6% respectively. In intensively treated patients, OS was significantly inferior (p < 0.001) in t-AML as compared to de novo AML (...
Researchers observed that patients aged 80 years and older with acute myeloid leukemia who were treated with venetoclax and a hypomethylating agent had prolonged overall survival. Recent study results demonstrate that standard of care treatment for acute myeloid leukemia (AML) is both safe and ...
The panelists agreed that chemotherapy and transplantation will be mainstays of treatment for now, but they believe that the addition of targeted therapies would improve outcomes. “I think the survival curves are going up, not just because of supportive care, but because in fact we understand th...
metastatic spread and is characterized by tremendous molecular, immunological, and clinical heterogeneity.1 The treatment landscape of AML has changed dramatically in recent years.2 However, most patients eventually relapse and have disappointing outcomes, with a 5-year overall survival (OS) rate of ...
biomarkers such as GPR56 on CD8 + T cells associated with improved survival further illustrates the capability of scRNA-seq to monitor immune recovery and optimize donor cell selection (Root et al.2024). This will open up avenues for better stratification and personalized treatment approaches ...
"This is very good because in general these patients are left without any option," Dr. Rocha told Medscape. ALL patients receiving unrelated cord blood transplantation (UCBT) had a significantly higher 2-year leukemia-free survival (LFS) rate compared with haplo patients (36% vs 13%;P= ....